Zafgen, Inc., a Cambridge, Mass.-based pharmaceutical company developing novel obesity therapeutics, has closed a $33m Series C financing.
The round was led by existing investors Atlas Venture and Third Rock Ventures.
The company intends to use the funds to advance its pipeline and develop its lead methionine aminopeptidase 2 (MetAP2) inhibitor for the treatment of severe obesity into Phase 2 clinical studies.
Founded in 2005, and led by president and CEO Thomas Hughes, Ph.D., Zafgen is pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism. Its approach focuses on restoring control of key metabolic processes, releasing stored fat which then is used by the body as fuel.
FinSMEs
07/07/2011